Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. uri icon

Overview

publication date

  • July 3, 2021

Research

keywords

  • Anaplastic Lymphoma Kinase
  • Carbazoles
  • Drug Resistance, Neoplasm
  • Lung Neoplasms
  • Piperidines
  • Protein Kinase Inhibitors
  • Trastuzumab

Identity

Scopus Document Identifier

  • 85111516381

Digital Object Identifier (DOI)

  • 10.1016/j.cllc.2021.06.012

PubMed ID

  • 34330640

Additional Document Info

volume

  • 23

issue

  • 2